fool.com · 16 jul

Johnson & Johnson vs. Eli Lilly and: Which Pharma Giant Stock Is a Better Buy in 2026?

One generates steady cash flow with a lower valuation; the other is growing at 45% but carries higher leverage.

marketbeat.com · 12 jul

Teva Pharmaceutical Industries' Anti-IL-15 Antibody Shows Promise in Vitiligo Study

Teva Pharmaceutical Industries NYSE: TEVA said its internally developed anti-IL-15 antibody produced encouraging 24-week efficacy results in a phase 1b proof-of-concept study for vitiligo, as the company highlighted the program as part of its broader shift toward a biopharma-focused growth strategy.

fool.com · 9 jul

Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?

Novartis AG maintains a highly profitable portfolio of innovative medicines with significant net margins. Teva Pharmaceutical Industries is executing a turnaround focused on biosimilars and high-growth innovative assets.

gurufocus.com · 9 jul

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis

Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG tod

businesswire.com · 9 jul

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis

TEL AVIV, Israel & ZUG, Switzerland--(BUSINESS WIRE)--Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics' proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics' proven bios.

globenewswire.com · 9 jul

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis

Teva secures exclusive global rights to commercialize Polpharma Biologics' biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations. Agreement advances Teva's Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.

benzinga.com · 8 jul

Bill Ackman Says Next $1 Trillion Company Will Come From Israel – ‘Imagine if Silicon Valley Was a Country'

In a recent interview, legendary investor Bill Ackman was asked about why he was bullish on the economy of Israel. The question comes with Ackman owning around a 5% stake in the Tel Aviv Stock Exchange.

seekingalpha.com · 7 jul

Teva Pharmaceutical Industries Limited (TEVA) Discusses Anti-IL-15 Antibody Phase Ib 24-Week Efficacy Results in Vitiligo and Planned Advancement to Phase 2b Transcript

Teva Pharmaceutical Industries Limited (TEVA) Discusses Anti-IL-15 Antibody Phase Ib 24-Week Efficacy Results in Vitiligo and Planned Advancement to Phase 2b Transcript